Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care
Jointly provided by
Support for this activity has been provided through educational grants from Amgen and Celgene Corporation.
Release date: 1/26/2018
Expiration date: 1/26/2019
Estimated time to complete: 2.5 hours
Improving outcomes for patients with multiple myeloma requires building on the foundation of current therapies with new agents and combinations, recognizing the nature of each individual patient’s disease, and providing a personalized approach to treatment. This activity uses evidence-based presentations and case study vignettes to present the latest information on selecting the most appropriate therapy based on patient profile, clinical evidence, and assessment of risk-versus-benefit.
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.
At the conclusion of this activity, participants should be better able to:
- Evaluate current clinical evidence on precision medicine
- Define patient prognosis and risk stratification utilizing R-ISS, FISH, and imaging
- Select treatment combinations in the frontline setting based on risk and patient-specific characteristics
- Assess treatment response to induction therapy and determine which patients will benefit from consolidation and/or maintenance therapy
- Select an appropriate course of therapy for patients who have relapsed from or become refractory to initial treatment
Paul G. Richardson, MD—Program Co-Chair
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
A. Keith Stewart, MBChB, MRCP, FRCPC, MBA—Program Co-Chair
Carlson and Nelson Endowed Director,
Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Jesus G. Berdeja, MD
Director, Multiple Myeloma Research
Senior Investigator, Hematologic Malignancies
Sarah Cannon Research Institute
Nina Shah, MD
Associate Professor of Clinical Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California
Peter Voorhees, MD
Director, Outreach for Hematologic Malignancies
Plasma Cells Disorder Program
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Carolinas HealthCare System
Charlotte, North Carolina
Katja Weisel, MD
Professor of Internal Medicine
University Hospital Tübingen
Head, Tübingen University Myeloma Center
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Paul G. Richardson, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Bristol-Myers Squibb, Celgene, Genmab, Janssen, Novartis, Takeda
A. Keith Stewart, MBChB, MRCP, FRCPC, MBA, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, Bristol-Myers Squibb, Celgene, Janssen
Jesus G. Berdeja MD, has disclosed the following relevant financial relationships:
Research Grant: Amgen, AbbVie, Acetylon, Bluebird, Bristol-Myers Squibb, Celgene, Constellation, Curis, Janssen, Novartis, Takeda, Teva, Vivolux
Nina Shah, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Celgene, Indapta Therapeutics, Takeda
Research Grant: Celgene
Stock Ownership: Indapta Therapeutics
Peter Voorhees, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Celgene, Janssen, Takeda
Speakers Bureau: Amgen, Celgene, Janssen
Katja Weisel, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Takeda
Research Grant: Amgen, Celgene, Janssen, Sanofi
Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
Mary DeRome, Director of Medical Communications and Education, has disclosed no relevant financial relationships.
Anne Quinn Young, MPH, Vice President of Development & Strategic Partnerships, has disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Kristen Petro Slade, Director of Operations, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Amgen, or Celgene Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Amgen, and Celgene Corporation do not recommend the use of any agent outside the labeled indications.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6198-18-T.
- Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser (PC): Google Chrome, Internet Explorer 9 or higher, or Firefox 26 or higher
- Internet browser (Mac): Google Chrome, Firefox 26 or higher, or Safari 5 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required
© 2018. This CME-certified program is held as copyrighted by Penn State College of Medicine and RedMedEd. Through this notice, Penn State College of Medicine and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.